Ken Griffin Regencell Bioscience Holdings LTD Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Regencell Bioscience Holdings LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 41,200 shares of RGC stock, worth $519,120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,200Holding current value
$519,120% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RGC
# of Institutions
22Shares Held
625KCall Options Held
73.8KPut Options Held
105K-
Geode Capital Management, LLC Boston, MA420KShares$5.29 Million0.0% of portfolio
-
Squarepoint Ops LLC New York, NY51.2KShares$645,7370.0% of portfolio
-
Discovery Capital Management, LLC South Norwalk, CT46.2KShares$581,6910.06% of portfolio
-
Xtx Topco LTD London, X038.7KShares$488,0610.03% of portfolio
-
Morgan Stanley New York, NY37.8KShares$476,8090.0% of portfolio
About Regencell Bioscience Holdings Ltd
- Ticker RGC
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,012,900
- Market Cap $164M
- Description
- Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated...